scholarly journals Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan

2020 ◽  
Vol 92 (12) ◽  
pp. 3475-3487 ◽  
Author(s):  
Saima Mushtaq ◽  
Atika Mansoor ◽  
Muhammad Umar ◽  
Amjad Khan ◽  
Saima Siddiqi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Life Experience ◽  
Antiviral Agents ◽  
Real Life ◽  
Clinical Practices ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C: Real-life Data

2021 ◽  
Vol 27 (2) ◽  
pp. 42-48
Author(s):  
Ayhan Balkan ◽  
Yasemin Balkan ◽  
Abdullah Emre Yıldırım ◽  
Buğra Tolga Konduk ◽  
Sezgin Barutçu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Real Life ◽  
Direct Acting Antiviral ◽  
Life Data ◽  
Real Life Data ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Direct-acting antiviral agents in the treatment of chronic Hepatitis C – Real-life experience from clinical practices in Pakistan

2019 ◽  
Author(s):  
Saima Mushtaq ◽  
Atika Mansoor ◽  
Saima Siddiqi ◽  
Amjad Khan ◽  
Sobia Manzoor
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Decompensated Cirrhosis ◽  
Clinical Practices ◽  
Genotype 3 ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Abstract Background: This study aims to evaluate the clinical effectiveness in terms of sustained virological response (SVR), predictors of SVR and safety of available second generation generic direct-acting antivirals in Pakistani chronic Hepatitis C patients.Methods: This is a retrospective study conducted in multiple centers of Pakistan from January 2015 to January 2019. The samples include patients infected with chronic hepatitis C virus, regardless of virus genotype, cirrhosis, or prior treatment. Statistical analysis was performed to compare the effectiveness among the direct-acting antiviral agents (DAAs) based treatments and also to reveal the factors influencing the achievement of SVR.Results: A total of 993 patients were included in the present study, with the majority receiving sofosbuvir with daclatasvir (95%), sofosbuvir with daclatasvir and ribavirin (4%) and sofosbuvir with ribavirin (1%). There were 96% cases of chronic hepatitis, 3% cases compensated cirrhosis and 1% cases of decompensated cirrhosis. Genotype 3 (99.6%) was the most common genotype. Overall SVR after 12 weeks was 98% for all treatment regimens. High SVR12 was observed with sofosbuvir in combination with daclatasvir (98.5%), then sofosbuvir in combination with daclatasvir and ribavirin (90.2%) and sofosbuvir in combination with ribavirin (75%). SVR rates were high in CHC patients (98.2%) as compared to cirrhotic patients (92.1%) and it was high in treatment naive (98.8%) then IFN experienced patients (90.1%). In multivariate binary logistic regression analysis, patients’ education status, treatment strategy, viral load and ALT had statistically significant association with SVR at 12 weeks. No major adverse events occurred which required treatment discontinuation. Conclusion: Generic oral DAAs (sofosbuvir with daclatasvir) achieved higher SVR12 rates and were well tolerated in this large real‐world cohort of genotype 3 infected patients.

scholarly journals Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Gang Ning ◽  
Yi-ting Li ◽  
You-ming Chen ◽  
Ying Zhang ◽  
Ying-fu Zeng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Nk Cells ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Healthy Controls ◽  
Direct Acting Antiviral ◽  
Inflammatory Monocytes ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Objective. Up to now, little was known about the immunological changes of chronic hepatitis C (CHC) patients treated with direct-acting antiviral agents (DAAs); we try to explore the effect of DAAs on the frequency of monocytes, NK cells, and cytokines that promote their activation. Methods. 15 treatment-naive CHC patients and 10 healthy controls were recruited. Patients were examined before DAAs therapy (0 w) and at week 4 (4 w) and week 12 (12 w) of therapy. Percentage of monocytes and NK cells of the peripheral blood was analyzed by flow cytometry. Serum cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 were measured by enzyme linked immunosorbent assay. Results. The frequency of CD3–CD16+CD56+ NK cells and classic CD14++CD16− monocytes decreased, while CD14+CD16+ monocytes and cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 increased at 0 w compared to healthy controls. During DAAs treatment, the decreased NK cells and classic monocytes gradually increased to normal levels; the increased inflammatory monocytes and cytokines IL-12 and CXCL11 decreased to normal levels, but the increased cytokines IL-18, CXCL10, sCD14, and sCD163 still remained at high levels at 12 w though they decreased rapidly from 0 w. Conclusion. Our results showed that DAAs treatment attenuated the activation of monocytes and NK cells in CHC patients. Trial registration number is NCT03063723.

Progress and Barriers Towards Elimination of Chronic Hepatitis C in Children

2020 ◽  
Author(s):  
Magdalena Pluta ◽  
Maria Pokorska-Śpiewak ◽  
Małgorzata Aniszewska ◽  
Barbara Kowalik-Mikołajewska ◽  
Magdalena Marczyńska
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Population Level ◽  
Direct Acting Antiviral ◽  
Current State ◽  
Direct Acting ◽  
Mother To Child ◽  
Direct Acting Antiviral Agents

AbstractChronic hepatitis C (CHC) is a global health burden. Mother-to-child transmission (MTCT) accounts for most HCV infections in pediatric patients. Spontaneous viral clearance may occur in early childhood but is uncommon thereafter. Infection is usually asymptomatic during childhood, although without an effective treatment, vertically infected children may develop serious liver complications including cirrhosis and hepatocellular carcinoma in adulthood. Despite the lack of vaccine against hepatitis C and effective post-exposure methods of prevention of MTCT, treatment with direct-acting antiviral agents (DAAs) raised the prospect of eliminating HCV on a population level. Highly effective, well-tolerated, oral, and interferon-free regimens of short duration have revolutionized treatment of CHC. However, access to these therapies might be limited because of its high cost. In this review, we provide the current state of knowledge on the epidemiology, testing, monitoring and treating of HCV in children. We outline the remaining gaps in therapy and barriers to disease eradication.

Sign in / Sign up

Export Citation Format

Share Document